CTLA4 and melanoma: Immune checkpoint inhibitors (ICIs) represent a breakthrough treatment of advanced (i.e. irresectable metastatic) melanoma, as the use of anti-PD-1 anti-CTLA-4 combination therapy increases median overall survival (OS) from 6-9 months to nearly six years [1–4].